2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 720

Interkeukin-6 Level in Cerebrospinal Fluid As a Biomarker for Systemic Lupus Erythematosus Patients with Longitudinally Extensive Transverse Myelitis like Neuromyelitis Optica Spectrum Disease
Abstract Number: 721

The Burden of Renal Arteriosclerosis in Lupus Nephritis: A Cohort Study Examining Prevalence and Predictors of Renal Arteriosclerosis
Abstract Number: 722

Increased Blood Pressure Visit-to-Visit Variability in Patients with Systemic Lupus Erythematosus: Association with Inflammation, Comorbidities and Increased Mortality
Abstract Number: 723

Patient-Reported Cognitive Screen Does Not Identify Cognitive Sub-Domains: Exploration of the Subscale Structure of the Perceived Deficits Questionnaire in a Systemic Lupus Erythematosus Cohort
Abstract Number: 724

Are Traditional Biomarkers of Lupus Associated with Renal Pathology in Lupus Nephritis?
Abstract Number: 725

Preliminary Population-Based Incidence and Prevalence Estimates of Primary Discoid Lupus and Cutaneous Lupus Erythematosus from the Manhattan Lupus Surveillance Program
Abstract Number: 726

Anti-Retinoblastoma Protein Antibody Is Protective Against Lupus Nephritis
Abstract Number: 727

Increased Risk of Coronary Artery Disease Among Patients with Class III Lupus Nephritis: A Retrospective Study of Patients at the University of North Carolina at Chapel Hill
Abstract Number: 728

A Higher Activity Index at Initial Renal Biopsy Is Associated with Rapid Progression to Renal Failure in Patients with Refractory Lupus Nephritis
Abstract Number: 729

Atherosclerotic Vascular Events in SLE – an Evolving Story
Abstract Number: 730

Accrual of Atherosclerotic Vascular Events over 10 Years in a Multicentre Inception SLE Cohort
Abstract Number: 731

Clinical Characteristics and Neurophysiological Patterns of Peripheral Neuropathies in Patients with Systemic Lupus Erythematosus: A Single Center Experience
Abstract Number: 732

Impact of Disease Course on Atherosclerotic Vascular Events, Osteoporosis and Osteonecrosis in Systemic Lupus Erythematosus
Abstract Number: 733

Advanced Chronic Kidney Disease in Lupus Nephritis: Factors Leading to Progression
Abstract Number: 734

The Role of Micro-RNA 142-3p Expression in Lupus Nephritis in an Egyptian Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].